Insider Selling: Surrozen (NASDAQ:SRZN) COO Sells 1,566 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) COO Charles Williams sold 1,566 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $19.87, for a total value of $31,116.42. Following the completion of the transaction, the chief operating officer owned 12,982 shares in the company, valued at $257,952.34. This represents a 10.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Surrozen Stock Performance

Shares of SRZN stock traded up $0.57 during trading on Tuesday, hitting $19.67. 78,574 shares of the company were exchanged, compared to its average volume of 85,990. The business’s 50-day simple moving average is $17.64 and its 200 day simple moving average is $13.39. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $24.94.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The company had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Research analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surrozen

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC increased its position in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after buying an additional 3,424 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares in the last quarter. Acuta Capital Partners LLC increased its holdings in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares during the last quarter. Stonepine Capital Management LLC increased its holdings in shares of Surrozen by 7.1% during the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after acquiring an additional 20,247 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Surrozen by 37.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 88,653 shares of the company’s stock valued at $1,034,000 after acquiring an additional 24,000 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SRZN shares. Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Finally, Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.